VACHW Overview

Business Combination Announcement: Voyager Acquisition Corporation has announced the approval of its business combination with Verax BioTech.

Strategic Partnership: This merger aims to enhance Voyager's capabilities and expand its market presence in the biotechnology sector.

Partnership Announcement: VERAXA Biotech AG has formed a co-discovery alliance with OmniAb, Inc. to develop a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors, combining their respective technologies for enhanced cancer therapy development.

Business Combination Plans: VERAXA is set to become publicly traded through a business combination with Voyager Acquisition Corp., aiming to leverage strategic partnerships and innovative technologies in the healthcare sector to drive growth and deliver new therapeutic solutions.

VERAXA's Business Combination: VERAXA Biotech AG is set to merge with Voyager Acquisition Corp., creating a publicly traded biopharmaceutical company focused on next-generation cancer therapies, with an estimated pre-money equity value of $1.3 billion and plans for NASDAQ listing under the ticker "VERX" by Q4 2025.

Innovative Cancer Therapies: The company is advancing its proprietary BiTAC platform to develop novel antibody-drug conjugates (ADCs) and bispecific T-cell engagers (TCEs), targeting significant growth markets in cancer therapy, with a robust pipeline including nine programs currently in various stages of development.